DE60100625T2 - Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina - Google Patents

Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina Download PDF

Info

Publication number
DE60100625T2
DE60100625T2 DE60100625T DE60100625T DE60100625T2 DE 60100625 T2 DE60100625 T2 DE 60100625T2 DE 60100625 T DE60100625 T DE 60100625T DE 60100625 T DE60100625 T DE 60100625T DE 60100625 T2 DE60100625 T2 DE 60100625T2
Authority
DE
Germany
Prior art keywords
retinal
rats
retina
compounds
dpat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60100625T
Other languages
German (de)
English (en)
Other versions
DE60100625D1 (de
Inventor
J. Robert COLLIER
A. Michael KAPIN
R. Mark HELLBERG
R. Thomas DEAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DE60100625D1 publication Critical patent/DE60100625D1/de
Publication of DE60100625T2 publication Critical patent/DE60100625T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
DE60100625T 2000-03-17 2001-02-23 Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina Expired - Lifetime DE60100625T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US190279P 2000-03-17
PCT/US2001/005700 WO2001070222A2 (fr) 2000-03-17 2001-02-23 Composes a activite agoniste sur le recepteur 5-ht1a destines au traitement des affections de la retine externe

Publications (2)

Publication Number Publication Date
DE60100625D1 DE60100625D1 (de) 2003-09-25
DE60100625T2 true DE60100625T2 (de) 2004-02-26

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60100625T Expired - Lifetime DE60100625T2 (de) 2000-03-17 2001-02-23 Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina

Country Status (19)

Country Link
EP (3) EP1263434A1 (fr)
JP (5) JP2003527423A (fr)
KR (3) KR20030016239A (fr)
CN (2) CN1198605C (fr)
AR (1) AR028258A1 (fr)
AT (1) ATE247507T1 (fr)
AU (5) AU2001238552A1 (fr)
BR (3) BR0109193A (fr)
CA (3) CA2400637A1 (fr)
DE (1) DE60100625T2 (fr)
DK (1) DK1263504T3 (fr)
ES (1) ES2204848T3 (fr)
HK (1) HK1051504A1 (fr)
MX (3) MXPA02009071A (fr)
PL (1) PL203709B1 (fr)
PT (1) PT1263504E (fr)
TW (1) TWI268777B (fr)
WO (3) WO2001070223A1 (fr)
ZA (1) ZA200206350B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763619B2 (en) 2000-03-17 2010-07-27 Alcon, Inc. Compounds with 5-HT1A activity useful for treating disorders of the outer retina

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
KR20030016239A (ko) * 2000-03-17 2003-02-26 알콘, 인코퍼레이티드 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
WO2004054572A2 (fr) 2002-12-13 2004-07-01 Alcon, Inc. Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
EP1617838A4 (fr) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp Composition pour administration orale contenant un derive d'alkylene dioxybenzene
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
TW200520760A (en) 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1792629A4 (fr) 2004-08-25 2010-08-25 Takeda Pharmaceutical Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci
WO2006062839A1 (fr) 2004-12-08 2006-06-15 Alcon, Inc. Utilisation de dioxindoindazoles et de dioxoloindazoles pour traiter le glaucome
WO2008117269A2 (fr) 2007-03-28 2008-10-02 Atir Holding S.A. Composés hétérocycliques comme agents sérotoninergiques et dopaminergiques et leurs utilisations
EP2742936A1 (fr) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique condensé et son utilisation
WO2008024846A2 (fr) * 2006-08-25 2008-02-28 Allergan, Inc. Compositions de brimonidine et de timolol
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US20120322882A1 (en) 2009-11-09 2012-12-20 Allergan, Inc. Compositions And Methods For Stimulating Hair Growth
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
JP2022523774A (ja) 2019-02-27 2022-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
WO2023118544A1 (fr) * 2021-12-23 2023-06-29 Cilcare Dev Dérivés de 4-phényl-tétrahydropyridine pour le traitement de troubles auditifs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (fr) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
KR20030016239A (ko) * 2000-03-17 2003-02-26 알콘, 인코퍼레이티드 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763619B2 (en) 2000-03-17 2010-07-27 Alcon, Inc. Compounds with 5-HT1A activity useful for treating disorders of the outer retina

Also Published As

Publication number Publication date
TWI268777B (en) 2006-12-21
EP1263434A1 (fr) 2002-12-11
JP2003527427A (ja) 2003-09-16
WO2001070230A3 (fr) 2002-04-25
HK1051504A1 (en) 2003-08-08
EP1263504B1 (fr) 2003-08-20
CN1418100A (zh) 2003-05-14
CA2400639A1 (fr) 2001-09-27
JP2011153158A (ja) 2011-08-11
PL358306A1 (en) 2004-08-09
KR20030009390A (ko) 2003-01-29
DK1263504T3 (da) 2003-12-08
AR028258A1 (es) 2003-04-30
ZA200206350B (en) 2003-08-08
BR0109193A (pt) 2003-05-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
ATE247507T1 (de) 2003-09-15
MXPA02009071A (es) 2003-05-23
CA2399985A1 (fr) 2001-09-27
WO2001070222A3 (fr) 2002-07-25
CN1418121A (zh) 2003-05-14
KR20020082885A (ko) 2002-10-31
PT1263504E (pt) 2003-12-31
BR0109230A (pt) 2003-06-03
AU2001239836A1 (en) 2001-10-03
WO2001070230A2 (fr) 2001-09-27
JP2003527423A (ja) 2003-09-16
WO2001070223A1 (fr) 2001-09-27
JP2003527422A (ja) 2003-09-16
PL203709B1 (pl) 2009-11-30
CN1198605C (zh) 2005-04-27
DE60100625D1 (de) 2003-09-25
KR20030016239A (ko) 2003-02-26
WO2001070222A2 (fr) 2001-09-27
EP1267878A2 (fr) 2003-01-02
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
KR100749191B1 (ko) 2007-08-13
AU2005202600B2 (en) 2008-07-31
MXPA02009072A (es) 2003-03-12
JP2011037901A (ja) 2011-02-24
AU4531001A (en) 2001-10-03
CA2400639C (fr) 2011-08-16
MXPA02009073A (es) 2003-03-12
CA2400637A1 (fr) 2001-09-27
ES2204848T3 (es) 2004-05-01
EP1263504A2 (fr) 2002-12-11
JP4789231B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
DE60100625T2 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE60024407T2 (de) (2-imidazolin-2-yl-amino)quinoxaline zur behandlung von neuralen verletzungen
AU2001245310A1 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
US7763619B2 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
AT394190B (de) Phenylcarbamate
DE69636012T3 (de) Verwendung von (2-imidazolin-2-yl-amino)quinoxalinen zur behandlung von augennervverletzung
DE69912790T2 (de) Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
DE69530933T2 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE602004005617T2 (de) Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
DE60101265T2 (de) Behandlung von augenschmerzen
DE2901477A1 (de) Thienohydantoinderivate und diese enthaltende arzneimittel
DE3805744C2 (de) Phenylcarbamate zur Hemmung der Acetylcholinesterase
EP1067965B1 (fr) Composition pharmaceutique pour traiter l'apoplexie cerebrale et le traumatisme craniocerebral
JP2002528416A (ja) 外網膜の疾患の治療
DE69229688C5 (de) Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten
DE60006584T2 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DE69932834T2 (de) Neue Peptide
DE60213365T2 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60217870T2 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
DE60319021T2 (de) Verfahren zur Behandlung von Sepsis
DE3844992B4 (de) Hydrogentartrat eines Phenylcarbamats
DE60012163T2 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
MXPA01004175A (en) Treatment of disorders of the outer retina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition